In a groundbreaking first, psilocybin is entering gastroenterology. Dr. Erin Mauney leads a pioneering study exploring how psychedelic therapy could transform treatment for millions suffering from treatment-resistant Irritable Bowel Syndrome, offering new hope for gut-brain disorders.
The Joint Committee on Vaccination and Immunisation (JCVI) has advised that all under 40s should be offered an alternative to the Oxford/AstraZeneca vaccine following blood clot risk.
A new study has revealed that new medicines and vaccines approved for use in the United States are often unavailable in countries that helped to develop them.
We spoke with Dr Matthew Duchars, CEO of the UK’s first dedicated Vaccines Manufacturing and Innovation Centre (VMIC), about their work not only to provide an integral response to COVID-19, but as a centre of excellence advancing the vaccine sector on a global scale.
We spoke with Tony Cecchin, Vice President and General Manager of Global Supplies at Zebra Technologies and President of Temptime Corporation, and Chris Caulfield, Vice President of Temptime Operations about their work supporting front-line workers and easing the shipment of medical products through the supply chain.
Rick Clayton, Technical Director, AnimalhealthEurope, unpacks Benchmarking Regulatory systems governing veterinary medicines in this the first of a series of three articles.
Professor Luis Diestre discusses the research and findings of his European Research Council funded Illegal Pharma Project, focussing on the ever popular market for counterfeit pharmaceuticals.
Michael Morrison, Senior Researcher in Social Science at the University of Oxford, illustrates the importance of emerging biomedical innovations in the UK.
Ruth Smith CEO of Active Care Group and its Christchurch Group division discusses the new highly virulent variant of COVID, vaccinations, and infection prevention and control (IPC).
